Filtrer vos résultats
- 3
- 2
- 1
- 3
- 2
- 1
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trialthe 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.505P, ⟨10.1093/annonc/mdx393.031⟩
Communication dans un congrès
hal-01632415v1
|
||
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialEuropean Journal of Cancer, 2018, 104, pp.108-116. ⟨10.1016/j.ejca.2018.09.006⟩
Article dans une revue
hal-01960176v1
|
|||
Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver MetastasesUltraschall in der Medizin, 2018, 39 (5), pp.544-558. ⟨10.1055/s-0043-122497⟩
Article dans une revue
hal-01699242v1
|